These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 1461374)

  • 1. New insights into the cause of Parkinson's disease.
    Jenner P; Schapira AH; Marsden CD
    Neurology; 1992 Dec; 42(12):2241-50. PubMed ID: 1461374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases.
    Gu M; Owen AD; Toffa SE; Cooper JM; Dexter DT; Jenner P; Marsden CD; Schapira AH
    J Neurol Sci; 1998 Jun; 158(1):24-9. PubMed ID: 9667773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What process causes nigral cell death in Parkinson's disease?
    Jenner P
    Neurol Clin; 1992 May; 10(2):387-403. PubMed ID: 1584181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of mitochondria in the etiology and pathogenesis of Parkinson's disease.
    Mizuno Y; Ikebe S; Hattori N; Nakagawa-Hattori Y; Mochizuki H; Tanaka M; Ozawa T
    Biochim Biophys Acta; 1995 May; 1271(1):265-74. PubMed ID: 7599219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
    Hill WD; Arai M; Cohen JA; Trojanowski JQ
    J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease.
    Jenner P
    Acta Neurol Scand Suppl; 1993; 146():6-13. PubMed ID: 8333254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease.
    Pearce RK; Owen A; Daniel S; Jenner P; Marsden CD
    J Neural Transm (Vienna); 1997; 104(6-7):661-77. PubMed ID: 9444566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group.
    Jenner P; Dexter DT; Sian J; Schapira AH; Marsden CD
    Ann Neurol; 1992; 32 Suppl():S82-7. PubMed ID: 1510385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease.
    Dexter DT; Sian J; Rose S; Hindmarsh JG; Mann VM; Cooper JM; Wells FR; Daniel SE; Lees AJ; Schapira AH
    Ann Neurol; 1994 Jan; 35(1):38-44. PubMed ID: 8285590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson's disease.
    Ebadi M; Govitrapong P; Sharma S; Muralikrishnan D; Shavali S; Pellett L; Schafer R; Albano C; Eken J
    Biol Signals Recept; 2001; 10(3-4):224-53. PubMed ID: 11351130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons.
    Tompkins MM; Basgall EJ; Zamrini E; Hill WD
    Am J Pathol; 1997 Jan; 150(1):119-31. PubMed ID: 9006329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of iron in senescence of dopaminergic neurons in Parkinson's disease.
    Youdim MB; Riederer P
    J Neural Transm Suppl; 1993; 40():57-67. PubMed ID: 8294901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron accumulation in Parkinson's disease.
    Mochizuki H; Yasuda T
    J Neural Transm (Vienna); 2012 Dec; 119(12):1511-4. PubMed ID: 23070727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Incidental occurrence of Lewy bodies in the brains of elderly patients--the relevance to aging and Parkinson's disease].
    Wakabayashi K; Takahashi H; Oyanagi K; Ikuta F
    No To Shinkei; 1993 Nov; 45(11):1033-8. PubMed ID: 8135950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease.
    Trist BG; Hare DJ; Double KL
    Aging Cell; 2019 Dec; 18(6):e13031. PubMed ID: 31432604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The mechanism of Lewy body formation in Parkinson's disease].
    Wakabayashi K; Takahashi H
    Nihon Rinsho; 2000 Oct; 58(10):2022-7. PubMed ID: 11068441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidative stress and Parkinson's disease.
    Owen AD; Schapira AH; Jenner P; Marsden CD
    Ann N Y Acad Sci; 1996 Jun; 786():217-23. PubMed ID: 8687021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A guide to neurotoxic animal models of Parkinson's disease.
    Tieu K
    Cold Spring Harb Perspect Med; 2011 Sep; 1(1):a009316. PubMed ID: 22229125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.